PBPeter Bang

Peter Bang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter Bang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • A. P. Jonsson

    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

    1 shared publication
  • Anders Juul

    Department of Growth and Reproduction Copenhagen University Hospital ‐ Rigshospitalet Copenhagen Denmark

    1 shared publication
  • B. Kriström

    1 shared publication
  • C. Carlsson-Skwirut

    Department of Woman and Child Health, Pediatric Endocrinology Unit (Q2:08), Astrid Lindgren Children’s Hospital, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

    1 shared publication
  • Christine Carlsson-Skwirut

    Pediatric Endocrinology Unit, Department of Woman and Child Health, Karolinska Institute, Stockholm, Sweden

    1 shared publication
  • E. Cederlund

    Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

    1 shared publication

Latest Publications

  • A Comparison of Different Definitions of Growth Response in Short Prepubertal Children Treated with Growth Hormone

    by P. Bang, R. Bjerknes, J. Dahlgren, L. Dunkel, J. Gustafsson, A. Juul, B. Kriström, P. Tapanainen, V. Åberg

    Background: How to define poor growth response in the management of short growth hormone (GH)-treated children is controversial. Aim: Assess various criteria of poor response. Subjects and Methods: Short GH-treated prepubertal children [n = 456; height (Ht) SD score (SDS) ≤–2] with idiopathic GH deficiency (IGHD, n = 173), idiopathic short stature (ISS, n = 37), small for gestational age (SGA, n = 54), organic GHD (OGHD, n = 40), Turner syndrome (TS, n = 43), skeletal dysplasia (n = 15), other diseases (n = 46) or syndromes (n = 48) were evaluated in this retrospective multicenter study. Median age at GH start was 6.3 years and Ht SDS –3.2. Results: Median [25–75 percentile] first-year gain in Ht SDS was 0.65 (0.40–0.90) and height velocity (HtV) 8.67 (7.51–9.90) cm/year. Almost 50% of IGHD children fulfilled at least one criterion for poor responders. In 28% of IGHD children, Ht SDS gain was 0.5. Only IGHD patients with peak stimulated growth hormone level <3 µg/l responded better than those with ISS. A higher proportion of children with TS, skeletal dysplasia or born SGA had Ht SDS gain <0.5. Conclusion: Many children respond poorly to GH therapy. Recommendations defining a criterion may help in managing short stature patients.


  • A 30-kDa fragment of insulin-like growth factor (IGF) binding protein-3 in human pregnancy serum with strongly reduced IGF-I binding

    by M. Ahlsén, C. Carlsson-Skwirut, A. P. Jonsson, E. Cederlund, T. Bergman, P. Bang

    Proteolytic cleavage of insulin-like growth factor (IGF) binding protein (IGFBP)-3 during pregnancy is likely to have both IGF-dependent and -independent effects on maternal, placental and fetal growth and metabolism. A 30-kDa proteolytic IGFBP-3 fragment was isolated from third trimester pregnancy human serum and identified by N- and C-terminal amino acid sequence analysis and mass spectrometry to correspond to residues 1–212 of the parent protein. This fragment is the dominating IGFBP-3 immunoreactive species in pregnancy serum. The 30-kDa fragment was also detected in serum of non-pregnant women where it coexists with intact IGFBP-3. Using biosensor technology, (1–212)IGFBP-3 was found to have 11-fold lower affinity for IGF-I compared to intact IGFBP-3, while a 4-fold decrease in affinity was found for IGF-II. Tests with des(1–3)IGF-I suggest fast binding of IGF-I to the N-terminal region of IGFBP-3 and similar affinity to a slow binding site in the C-terminal region.


  • Open Access

    Normalization of the IGF-IGFBP Axis by Sustained Nightly Insulinization in Type 1 Diabetes

    by Klas Ekström, Jenny Salemyr, Ingmar Zachrisson, Christine Carlsson-Skwirut, Eva ÖrTqvist, Peter Bang

    OBJECTIVE—We sought to test the hypothesis that start of insulin glargine with sustained nightly insulin action results in changes in circulating concentrations of IGF-I and IGF binding proteins (IGFBPs) in adolescents with type 1 diabetes—changes that may support improvement of A1C.